<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04206163</url>
  </required_header>
  <id_info>
    <org_study_id>2019-001300-38</org_study_id>
    <nct_id>NCT04206163</nct_id>
  </id_info>
  <brief_title>Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis</brief_title>
  <official_title>Somatostatin Receptor Imaging in Inflammatory Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective imaging study investigates the diagnostic ability of Gallium-68 DOTA-TOC
      (68Ga-DOTA-TOC) positron emission tomography/computed tomography (PET/CT) in the clinical
      work-up of patients with 1) clinically suspected acute myocarditis (n=30-40) and 2)
      clinically suspected cardiac sarcoidosis (n=30-40) using clinical diagnostic criteria as well
      as endomyocardial biopsy as reference. Furthermore, 68Ga-DOTA-TOC PET/CT findings will be
      compared with results from contrast-enhanced magnetic resonance imaging (MRI) and in case of
      cardiac sarcoidosis even Fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT, which are both
      performed as part of the clinical routine work-up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of 68Ga-DOTA-TOC PET/CT versus contrast-enhanced MRI in patients with clinically suspected acute myocarditis (using clinical diagnostic criteria as well as endomyocardial biopsy as reference)</measure>
    <time_frame>Completion of enrollment, approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of 68Ga-DOTA-TOC PET/CT versus contrast-enhanced MRI in patients with clinically suspected acute myocarditis (using clinical diagnostic criteria as well as endomyocardial biopsy as reference)</measure>
    <time_frame>Completion of enrollment, approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity of 68Ga-DOTA-TOC PET/CT versus contrast-enhanced MRI and 18F-FDG PET/CT in patients with clinically suspected cardiac sarcoidosis (using clinical diagnostic criteria as well as endomyocardial biopsy as reference)</measure>
    <time_frame>Completion of enrollment, approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of 68Ga-DOTA-TOC PET/CT versus contrast-enhanced MRI and 18F-FDG PET/CT in patients with clinically suspected cardiac sarcoidosis (using clinical diagnostic criteria as well as endomyocardial biopsy as reference)</measure>
    <time_frame>Completion of enrollment, approximately 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Myocarditis</condition>
  <condition>Cardiac Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Acute myocarditis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Included patients with clinically suspected acute myocarditis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI and endomyocardial biopsy (if clinically indicated) as part of the clinical routine work-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cardiac sarcoidosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Included patients with clinically suspected cardiac sarcoidosis (n=30-40) will undergo a 68Ga-DOTA-TOC PET/CT and a blood sample will be taken. Furthermore, participants will undergo a contrast-enhanced MRI, 18F-FDG PET/CT and endomyocardial biopsy as part of the clinical routine work-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>68Ga-DOTA-TOC PET/CT</intervention_name>
    <description>Somatostatin receptor imaging</description>
    <arm_group_label>Acute myocarditis</arm_group_label>
    <arm_group_label>Cardiac sarcoidosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Analysis of inflammatory biomarkers</description>
    <arm_group_label>Acute myocarditis</arm_group_label>
    <arm_group_label>Cardiac sarcoidosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness to participate in the study

          -  Provision of written informed consent

          -  All patients between the age of 18 and 85 of both genders

          -  Newly clinically suspected acute myocarditis or newly clinically suspected cardiac
             sarcoidosis with or without known extra-cardiac sarcoid

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Severe obesity (limited by the scanner)

          -  Other known significant cardiac disease, including previous myocarditis

          -  Known tumour disease, especially (neuro)endocrine tumours

          -  Terminal disease(s), advanced psychiatric disease and/or significant dementia

          -  Recent or current immunosuppressive treatment

          -  Recent or current somatostatin analogue (octreotide) therapy

          -  Known relative/absolute contraindications for contrast-enhanced MRI and/or PET/CT
             imaging

          -  Known contraindications for endomyocardial biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian L Polte, MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Entela Bollano, MD, PhD</last_name>
    <phone>+46-31-3421000</phone>
    <email>entela.bollano@vgregion.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>GÃ¶teborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niklas Bergh, MD, PhD</last_name>
      <phone>+46-31-3421000</phone>
      <email>niklas.bergh@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Christian L Polte, MD, PhD, MSc</last_name>
      <phone>+46-31-3421000</phone>
      <email>christian.polte@vgregion.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocarditis</keyword>
  <keyword>Cardiac sarcoidosis</keyword>
  <keyword>Inflammatory cardiomyopathy</keyword>
  <keyword>Cardiomyopathy</keyword>
  <keyword>Heart disease</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Somatostatin</keyword>
  <keyword>68Ga-DOTA-TOC</keyword>
  <keyword>Positron emission tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edotreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

